Braveheart Bio Targets $1.2 Billion Valuation in IPO
The heart-disease drug developer is seeking up to $318.8 million for clinical trials and research.
Archive
Search
Chai Discovery Raises $400 Million for AI-Designed Medicines
The molecular design startup reached a $3.8 billion valuation while expanding partnerships with major drugmakers.
Osanni Bio Raises $190 Million for a Multi-Program Therapeutics Platform
The biotechnology company is advancing seven programs and plans to form focused affiliates as individual assets reach clinical milestones.
SonoThera Raises $125 Million for Ultrasound-Delivered Genetic Medicines
The biotechnology company plans to move nonviral treatments for Duchenne muscular dystrophy and polycystic kidney disease toward clinical testing.
NewLimit Raises $435 Million to Advance Cellular Reprogramming Medicines
The longevity biotechnology company plans to move its first liver program toward human testing while expanding its discovery platform.
Spiral Therapeutics Raises $27 Million and Adds an Inner Ear Partnership
The clinical-stage company will advance its lead hearing program while working with Advanced Bionics on therapies delivered alongside cochlear implants.
The Biological Computing Co. Raises $25 Million to Develop Neuron-Based Computers
The Mission Bay startup is building laboratory systems that use living neurons for AI workloads, an ambitious alternative to conventional silicon.
